(AMEX: ONI), (NASDAQ: MELA), (NASDAQ: TRIB).

Turning Pennies into dollars: (AMEX: ONI), (NASDAQ: MELA), (NASDAQ: TRIB).

Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559

For more info: http://oni.realpennies.com

Oragenics, Inc. (AMEX: ONI)(February 12, 2008) announced Tuesday that seven shareholders who received warrants as part of their March 2006 investment in Oragenics have exercised stock warrants which will provide the company with an additional $0.5 million. The shareholders who exercised their warrants included two members of Oragenics' Board of Directors and a former Chief Executive Officer (CEO)/President. The company plans to use the proceeds of this warrant exercise to support its lead product development programs.

Dr. Jeffery Hillman, Oragenics' Chief Scientific Officer, stated, "We appreciate the confidence and support expressed by our shareholders, Board members, and our former CEO/President as our company continues to progress toward achieving its strategic goals." With the exercise of these warrants, approximately 1.1 million warrants from the March 2006 private placement have been exercised.

Company Management: Dr. Ronald P. Evens, interim CEO/President and Director, notified the Board of his intention to resign as CEO/President effective February 12, 2008, so that he can devote more time to the activities of his own company and his family. Dr. Evens will continue to serve as a member of Oragenics' Board of Directors. The Board of Directors thanked Ron Evens for his valuable service to Oragenics as interim CEO.

Mr. Gury announced that Mr. Stanley B. Stein, a recently appointed director, has accepted the role of interim CEO/President until a permanent CEO can be appointed. Dr. Jeffrey Hillman, Dotti Delfino and David Gury remain the CSO, CFO and Chairman, respectively. Finally, there have been no changes with regards to other employees or to the scientific and development team which will continue to work under Dr. Hillman's direction.

Oragenics, Inc. is a biopharmaceutical company with a pipeline of proprietary technologies. The Company has a number of products in discovery, preclinical and clinical development, with a concentration in the main therapeutic area of infectious diseases. Our core pipeline includes products and supporting platform technologies for use in the treatment and diagnosis of bacterial infections.

For more info: http://mela.realpennies.com

Electro-Optical Sciences, Inc. ("EOS") (NASDAQ: MELA)(February 12, 2008), a medical device company focused on the design and development of MelaFind , a non-invasive, point-of-care instrument to assist in the early diagnosis of melanoma, announced Tuesday the appointment of Tina Cheng-Avery to the Company's senior management team.

"Tina comes to us with over 20 years of experience in the commercialization of dermatology products from Aveeno, Neutrogena, Elizabeth Arden, and Pierre Fabre. Her insights into consumer behavior, the workings of the dermatologist's office, and market preparation will be invaluable to us as we continue pre-commercialization efforts and discussions with potential partners for the commercialization of MelaFind," said Joseph V. Gulfo, MD, MBA, President and CEO of Electro-Optical Sciences.

"I am thrilled to be joining EOS and working on MelaFind. It is an important product that I am confident will resonate with both patients and caregivers in the dermatology field," said Tina Cheng-Avery, Vice President of Commercialization. "In my experience in dermatology, the two things that matter most for a new product are patient demand and practice dynamics, both of which, I believe, are very favorable for MelaFind." Ms. Cheng-Avery joins EOS in the newly created position of Vice President of Commercialization from Pierre Fabre Dermo-Cosmetique USA/Genesis Pharmaceutical where she served as Vice President of Marketing and managed the Avne and Glytone dermo-cosmetic skincare product lines distributed through dermatologist and plastic surgeon offices.

Previously, Ms. Cheng-Avery was Global Marketing Director for Skin Care at Elizabeth Arden, Inc. where she managed a $300 million skin care portfolio. In addition, she led a collaboration between Elizabeth Arden and Allergen Pharmaceuticals and was responsible for launching Prevage Anti-Aging Treatment.

Other key positions she has held include Vice President of Marketing for Wella Personal Care of North America, group product director at Johnson & Johnson's Neutrogena Corporation, and Associate Brand Manager for Aveeno at S.C. Johnson & Family, Inc.

Ms. Cheng-Avery holds a Master of Business Administration degree from Northwestern University.

About Electro-Optical Sciences

EOS is a medical device company focused on designing and developing a non-invasive, point-of-care instrument to assist in the early diagnosis of melanoma. MelaFind features a hand-held imaging device that emits light of multiple wavelengths to capture images of suspicious pigmented skin lesions and extract data. Using sophisticated algorithms, the data are then analyzed against a proprietary database of melanomas and benign lesions in order to provide information to the physician and produce a recommendation of whether the lesion should be biopsied.

Melanoma is the deadliest of skin cancers, responsible for approximately 80% of all skin cancer deaths. Unless melanoma is detected early and excised with proper margins, the patient survival rate is poor, as there is currently no cure for advanced stage melanoma.

For more information on EOS, visit www.eosciences.com.

For more info: http://trib.realpennies.com

Trinity Biotech plc (NASDAQ: TRIB)(February 12, 2008), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announced Tuesday that Brendan Farrell, Chief Executive Officer will be speaking at the Roth Capital Partners 20th Annual OC Growth Stock Conference at 08:00 a.m. Pacific Time, on Tuesday the 19th of February. The event will be webcast and can be accessed on http://wsw.com/webcast/roth16/trib/

Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and blood coagulation disorders, and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com.

Read our full disclaimer at: http://www.realpennies.com/start.html

Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html

Sponsored by: http://www.isthemarketopen.com

RealPennies .

Telephone: 1-800-940-6559

Matt /at/ realpennies.com